Speed up biopharma approvals with Box Sign CFR 11
Blog post from Box
In the life sciences industry, ensuring regulatory compliance and maintaining the quality and efficacy of drugs and devices is crucial, but it often slows the adoption of digital transformation. Despite the introduction of the 21 CFR Part 11 regulation in 1997, which aimed to facilitate the use of electronic records and signatures, the transition from paper to digital has been sluggish, with biopharmaceutical companies still relying on multiple paper-on-glass solutions. The complexity of managing various cloud solutions, applications, and e-signature tools has further hindered efficiency. In response, Box has introduced Box Sign Part 11 e-signatures, a solution designed to simplify and streamline e-signature processes across the biopharma value chain. This new tool offers a secure, centralized platform for managing e-signatures on collaborative documents, enhancing workflow efficiency and reducing management overhead. Box Sign Part 11 e-signatures promise to improve user experiences and decrease costs, offering unlimited use across different R&D and manufacturing processes, while maintaining robust security standards.
No tracked trend matches for this post yet.
Use this post, company, and trend context to find content marketing opportunities, perform competitive analysis, or address product feature gaps via the Plushcap MCP server or the Plushcap API.